<DOC>
	<DOC>NCT01192399</DOC>
	<brief_summary>The objective of this study was to assess the safety and efficacy of eculizumab in hemolytic PNH patients. In addition, the pharmacokinetics (PK) and pharmacodynamic (PD) response of eculizumab was assessed and compared to overseas studies of eculizumab treatment in hemolytic PNH patients.</brief_summary>
	<brief_title>C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Japanese individuals at least 12 years of age Diagnosis of PNH &gt; 6 months One transfusion in the past two years for anemia or anemiarelated symptoms LDH level &gt;/= 1.5 x upper limit of normal within 12 weeks Platelet count &lt; 30,000/microliters Known or suspected hereditary complement deficiency History of hematopoietic stem cell transplant History of meningococcal disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>PNH</keyword>
	<keyword>Japan</keyword>
</DOC>